NABTT 0401 - BAY 43-9006 FOR PATIENTS WITH GLIOMA

NABTT 0401 - BAY 43-9006 适用于神经胶质瘤患者

• 批准号: 7603219
• 负责人: BURTON L NABORS
• 金额: $ 0.53万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-03-01 至 2008-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7603219
• 关键词: Adult; Angiogenic Factor; Anticonvulsants; BAY 43-9006; Computer Retrieval of Information on Scientific Projects Database; Convulsants; Cytochrome P450; Dose; Drug Kinetics; Enzymes; Epidermal Growth Factor Receptor; Family; Funding; Glioma; Grant; Growth; Growth Factor Receptors; Hepatic; Human; In Vitro; Institution; MAP Kinase Gene; Malignant Glioma; Maximum Tolerated Dose; Measures; Mediator of activation protein; Multienzyme Complexes; New Approaches to Brain Tumor Therapy Consortium; Pathway interactions; Patients; Phase; Phase II Clinical Trials; Platelet-Derived Growth Factor Receptor; Receptor Protein-Tyrosine Kinases; Recurrence; Research; Research Personnel; Resources; Route; Signal Pathway; Signal Transduction; Source; Toxic effect; United States National Institutes of Health; Upper arm; Week; cohort; day; inhibitor/antagonist; member; mutant; response; tumor; tumor progression

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. There are four primary objectives to this study. The first objective is to determine the maximum tolerated dose (MTD) of BAY 43-9006 when administered to adults with recurrent malignant glioma, receiving or not receiving anti-convulsants known to be metabolized by the P450 hepatic enzyme complex. The second objective is to assess and estimate the dose-related toxicities. Thirdly, to describe the pharmacokinetics of this route of administration, measuring BAY 43-9906, and to assess the pharmacokinetic difference between patients taking enzyme-inducing agents and those who are not. And lastly, to estimate overall survival. Malignant gliomas are characterized by alterations in mitogenic signaling pathways such as the EGFR (epidermal growth factor receptor) and the PDGFR (platelet derived growth factor receptor). The RAS/raf signaling pathway is an important mediator of responses to growth signals and angiogenic factors. This pathway is often aberrantly activated in human tumors due to presence of activated ras, mutant b-raf, or over expression of growth factor receptors. BAY 43-9006 is a potent inhibitor of c-raf, and wild-type and mutant b-raf in vitro. Additionally, further characterization of BAY 43-9006 tosylate revealed that this agent inhibits several receptor tyrosine kinases that are involved in tumor progression and p38a, a member of the MAPK family. Bay 43-9006 has been evaluated in multiple Phase I and Phase II studies in a variety of tumor types. To date, over 500 patients have been treated with single agent BAY 43-9006. BAY 43-9006 will be administered orally BID for 4 consecutive weeks. The 28-day period will represent one treatment cycle. The starting dose will be 200 mg BID. Patients will be stratified according to the use of cytochrome P450-inducing anticonvulsants in this study. Three patients per cohort in each arm of the study (3 from Group A and 3 from Group B) will be treated at the starting dose of 200 mg BID x 4 weeks until tumor progression. The dose will be escalated in a stepwise fashion with an expansion to a total of 6 patients at the putative MTD.

这个子项目是众多研究子项目之一